Ipamorelin (5 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Ipamorelin is a synthetic pentapeptide studied as a highly selective agonist of the growth hormone secretagogue receptor (GHSR-1a). The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published research, not a recommendation for use in humans or animals.

For a 5 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of roughly 1.67 mg/mL (~1,667 mcg/mL). At that fill, each 0.01 mL drawn on a U-100 insulin syringe equals 1 unit and delivers about 16.7 mcg, so a 100 mcg measurement lands at roughly 6 units and a 200 mcg measurement at roughly 12 units.

Standard (Gradual) Titration Schedule

The gradual schedule steps the daily amount up over several weeks, a pattern that lets a research model establish tolerability at each level before advancing. In the published handling context the compound is administered once daily, typically 30–60 minutes before rest on an empty stomach to align with the natural pulsatile GH window.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (~1.67 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Higher-Concentration) Reconstitution Schedule

Where a tighter fill is preferred — for example to keep small measurements above the 5-unit mark for accuracy — the same 5 mg vial can be reconstituted with a smaller volume of diluent. Adding 2.0 mL of bacteriostatic water yields 2.5 mg/mL (2,500 mcg/mL), which lowers the unit count at every step.

Supplies Needed

• Ipamorelin vials (5 mg): ~2 vials for an 8-week daily run; ~4 vials for 12 weeks; ~5 vials for a 16-week schedule.
• Insulin syringes (U-100, 0.3–0.5 mL): roughly 56 for 8 weeks, 84 for 12 weeks, 112 for 16 weeks (one fresh syringe per daily draw).
• Bacteriostatic water (10 mL): one bottle covers an 8-week run; two bottles for a 12–16 week schedule.
• Alcohol swabs: two 100-count boxes for 8–12 weeks; three for a 16-week schedule.

Protocol Overview

• Research goal: model pulsatile endogenous growth hormone release via selective GHSR-1a activation.
• Schedule: once-daily subcutaneous administration in the published handling model.
• Dose band: 100–250 mcg daily, with 200 mcg a common middle-ground reference point.
• Fill: 5 mg lyophilized, reconstituted to ~1.67 mg/mL with 3 mL diluent (or 2.5 mg/mL with 2 mL).
• Storage: −20 °C dry long-term; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the 100 mcg step and hold each level for one to several weeks before escalating.
• Keep administration on a fixed daily cadence — pre-rest, on an empty stomach — to align with the natural GH pulse window.
• Escalate only after tolerability is established at the prior step.
• Target the 200 mcg mid-band as the common reference dose in the literature.

Storage Instructions

Keep sealed lyophilized vials at −20 °C for long-term storage, protected from light; short-term holding at 2–8 °C is acceptable. Once reconstituted, refrigerate at 2–8 °C and use within about four weeks. Aliquots may be frozen at −20 °C for extended holding. Allow refrigerated solution to warm slightly before drawing and avoid repeated freeze-thaw cycles, which degrade the peptide.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Because the working concentration is dilute, double-check the unit count against the labelled mg/mL before each measurement.
• Document each draw — date, volume, remaining material — for reproducibility.

How Ipamorelin Works

Ipamorelin is a synthetic pentapeptide that binds the growth hormone secretagogue receptor (GHSR-1a) on the anterior pituitary, prompting the release of endogenous growth hormone in a pulsatile pattern that mirrors the body's own rhythm. In the published pharmacodynamic work, peak GH levels appear within roughly 40 minutes and return toward baseline within 2–3 hours, consistent with a circulating half-life of about 1.5–2.5 hours. Its defining feature is selectivity: unlike earlier secretagogues, it drives GH release without meaningfully elevating ACTH, cortisol or prolactin, which is why it is often described as the first selective GH secretagogue in the comparative literature.

Reported Benefits & Side Effects

Benefits observed in research

• Support for lean-mass accrual and recovery through GH-mediated anabolic signalling.
• Effects on fat metabolism and overall body composition in animal models.
• Improved gastric motility, reflected in study of postoperative ileus.
• Generally well tolerated at the doses examined, with no desensitisation of the GH-release mechanism reported across multi-week dosing.

Side effects reported

• Occasional mild injection-site reactions such as redness or swelling.
• Rarely, transient water retention or increased appetite.
• Overall low incidence at standard reference doses.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition in the study designs that pair GH secretagogues with body-composition endpoints.
• Combined resistance and aerobic activity to support the anabolic signal.
• Adequate sleep — the dominant natural GH pulse occurs during deep sleep — alongside standard hydration and stress controls.

Injection Technique (Reference Only)

• Swab the vial stopper and the chosen site with alcohol and let both dry.
• Draw the calculated dose, clear air bubbles, and insert subcutaneously at a 45–90° angle into a pinched skin fold (abdomen ~2 inches from the navel, thigh, upper arm or flank).
• Aspiration is not required for subcutaneous work; inject slowly, then withdraw and apply gentle pressure.
• Rotate sites systematically and dispose of sharps in an approved container immediately.

References

Related Protocols